NeoStem, Inc., a company engaged in the cellular therapy industry, said that Dr. Robin L. Smith, Chairman and CEO, was interviewed live on Clear Channel's "The Traders Network" hosted by Michael Yorba.
In a release, the Company said that this was Dr. Smith's second appearance on The Traders Network. In a two-part interview, Dr. Smith explained the Company's 2014 goals, 2013 achievements, and the increased visibility the Company is achieving in the cell therapy industry.
In a release, the Company noted:
When asked why investors are interested in NeoStem, Dr. Smith explained how NeoStem has addressed three key risks that investors often assess before investing in a stem cell company; financing, patient enrollment and manufacturing capabilities. NeoStem has addressed these risks by, first, raising over $40 million this past October in its latest round of fundraising. Second, completing enrollment in its Phase 2 clinical trial testing AMR-001, its lead product candidate for cardiovascular disease, demonstrating management's skill in advancing product candidates through the clinical trial regime. And lastly, as the Company has internal manufacturing capabilities through its wholly owned subsidiary, Progenitor Cell Therapy (PCT), there are lower risks and uncertainties associated with manufacturing its cell therapy candidates.
Yorba and Dr. Smith discussed NeoStem's pipeline of proprietary cell therapy products, which continues to develop, most notably, NeoStem's completion of enrollment in its PreSERVE AMI Phase 2 clinical trial in December 2013, investigating the Company's most advanced product candidate, AMR-001, in preserving heart function after a severe heart attack. Data read out is expected in Q3 2014, and the Company is also exploring AMR-001 for chronic heart failure and traumatic brain injury. NeoStem also continues to advance its T regulatory cell program with the goal of developing treatments for immune modulated diseases such as type 1 diabetes, and inflammatory conditions such as steroid resistant asthma. Finally, NeoStem continues to develop its very small embryonic-like stem cell (VSEL Technology) platform in preclinical models with the goal of advancing into early clinical studies to explore the therapeutic potential of VSEL Technology in indications such as bone repair, healing complex skin and soft tissue wounds, and age-related macular degeneration.
In 2013, for the second year in a row, NeoStem was named the number one fastest growing company and number eleven nationally on Deloitte's Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Deloitte looks at revenue and growth over a five year growth period as a benchmark. When Yorba asked Dr. Smith about winning this award, she noted that the Company was really proud to have won this award and to be in the company of such highly esteemed peer companies that were also in the running for the award.
Yorba and Dr. Smith also discussed NeoStem's model of growth. Instead of simply building the Company organically, NeoStem has grown through a series of acquisitions, and as such has become one of the fastest growing companies in its sector. NeoStem has completed five M&A transactions, one divestiture, and raised over 180 million dollars, enabling it to bring in key assets. As Dr. Smith explained, growing the Company in this manner has allowed NeoStem to acquire great talent, and the assets to potentially lead the industry. Speaking of NeoStem's revenue-generating operations through PCT, Dr. Smith said, "I think having the manufacturing is a real edge for us because we can generate revenues from the industry, we can lower the cost of goods, we can focus on things that the industry needs as a whole, and not only does it benefit our clients, but it benefits our internal development. We've created a very unique model that seems to be exciting to Wall Street and investors."
Interview Archive Segment 1 (9min, 37sec):
Interview Archive Segment 2 (10min, 41sec):
((Comments on this story may be sent to firstname.lastname@example.org))